SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH MODIFIED IMMUNE CELLS WITH ZINC FINGER NUCLEASES
SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-T Unprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials Richmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new …